{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:04Z","timestamp":1792172464854,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Thymoma-associated myasthenia gravis (TAMG) accounts for 15\u201320% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal response to conventional therapies. However, TAMG patients are underrepresented in clinical trials, leaving gaps in evidence for optimal treatment strategies. This study assessed the efficacy of complement inhibitors (CI) in TAMG population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed 23 TAMG patients who received CI, with a minimum follow-up of six months. Additionally, we randomly included 22 MG patients without thymoma, treated with CI, in the control group. Clinical outcomes were measured using Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at baseline, three, and six months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 23 TAMG patients, 21 initiated CI after thymectomy, with a median interval of eight years (IQR:2.5-15) post-surgery. Two patients achieved sufficient stabilization on CI to undergo thymectomy thereafter. The most frequent thymoma histological subtype was WHO type B2, detected in 43.5% of cases. Median MG-ADL score decreased from 11 (IQR:8-15) to 3 (IQR:2-5) and 4 (IQR:1-5) at three and six months, respectively (both p&amp;lt;0.001). Median QMG score decreased from 16 (IQR:14-22) to 10 (IQR: 5-11) at three and six months (both p&amp;lt;0.001). Prednisone dosage was tapered in 20 patients. No significant differences were observed between TAMG and MG patients without thymoma in MG-ADL, QMG and steroid reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CI demonstrated significant improvements in MG-ADL and QMG scores, along with a steroid-sparing effect, suggesting its potential as an effective treatment for this challenging subpopulation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1562419","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T05:19:11Z","timestamp":1744607951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Sofia","family":"Marini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Erra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fionda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Falso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Meacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000032502.89361.0c","article-title":"Thymoma in patients with MG: characteristics and long-term outcome","volume":"59","author":"Evoli","year":"2002","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1407830","DOI":"10.3389\/fmed.2024.1407830","article-title":"Long-term prognosis in patients with thymoma combined with myasthenia gravis: a propensity score-matching analysis","volume":"11","author":"Zhao","year":"2024","journal-title":"Front Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-3-239","article-title":"Thymoma: update for the new millennium","volume":"6","author":"Johnson","year":"2001","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-008-0158-y","article-title":"Myasthenia gravis and the thymus gland. A\u00a0historical review","volume":"8","author":"Raica","year":"2008","journal-title":"Clin Exp Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.05.22","article-title":"Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports","volume":"9","author":"Fukuhara","year":"2017","journal-title":"J Thorac Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to\u00a0treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0003-4975(01)02678-9","article-title":"Predictors of outcome in thymectomy for myasthenia gravis","volume":"72","author":"Budde","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13019-024-02511-6","article-title":"Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study","volume":"19","author":"Tian","year":"2024","journal-title":"J Cardiothorac Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675","article-title":"Performance of different criteria for refractory myasthenia gravis","volume":"28","author":"Tran","year":"2021","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52051","article-title":"Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis","volume":"11","author":"Tokuyasu","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17562864211001995","DOI":"10.1177\/17562864211001995","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1378080","article-title":"Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"15","author":"Katyal","year":"2024","journal-title":"Front Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: A study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit Int Med J Exp Clin Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T05:19:12Z","timestamp":1744607952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1562419"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1562419","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"1562419"}}